- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00406068
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be divided into 3 phases: Induction, Maintenance, and Follow-up.
The Induction Phase will cover a period of 6 weeks. During this time, patients will receive 6 weekly intravesical instillations of 8 mg MCC. The patients will be evaluated at month 3, at which time the patients will enter the Maintenance Phase. The Maintenance Phase will last from month 3 to month 24, and during this time, patients will receive weekly MCC instillations for three weeks at months 3, 6, 12, 18, and 24 and evaluations will be performed at months 3, 6, 9, 12, 15, 18, 21 and 24.
At month 3, the patient will be evaluated to assure that the disease is not progressing. Cytology, cystoscopy and biopsies will be performed to obtain adequate staging (if residual tumor persists). If the patient is disease-free, maintenance therapy will be initiated. Patients with non-muscle invasive tumors at month 3 will, at the discretion of the investigator, receive either a second 6-week induction course or a 3-week maintenance course. Patients who show progression to muscle invasive disease will be referred to other treatments.
At month 6 and thereafter at each evaluation visit, patients will be evaluated and managed according to the following results:
- Patients who are disease-free will continue on maintenance treatment.
- Patients who are not disease-free (evidence of papillary lesions, CIS or muscle invasive disease) will be withdrawn from further study treatment and will be referred to other therapies at the discretion of the investigator.
The final 36 months of the study is the Follow-up Phase. Evaluations will be performed at months 30, 36, 42, 48, 54 and 60.
Efficacy evaluations will include standard cystoscopy, biopsies and urine cytology. During the Maintenance Phase, standard cystoscopies will be performed at months 3, 6, 9, 12, 15, 18, 21 and 24 for the surveillance of bladder tumors. During the months that instillations will be performed, cystoscopies will be conducted only once at each of these months. During the Follow-up Phase, cystoscopies will be performed at months 30, 36, 42, 48, 54 and 60.
Mandatory bladder biopsies will be done for all patients at month 6.
During the course of the study, biopsies will be taken only if evident or suspicious lesions are seen during cystoscopy or in case of negative cystoscopy but positive cytology.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3V 1N1
- Andreou Research
-
Victoria, British Columbia, Canada, V8V 3N1
- Dr. Steinhoff Clinical Research
-
Victoria, British Columbia, Canada, V8T 5G1
- Can-Med Clinical Research
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 3J7
- Centre for Applied Urological Research
-
London, Ontario, Canada, N6A 5W9
- London Health Sciences Centre
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
Toronto, Ontario, Canada, M5G 2M9
- UNIVERSITY HEALTH NETWORK / PRINCESS MARGARET HOSPITAL
-
Toronto, Ontario, Canada, M6A 3B5
- The Male Health Center
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Jewish General Hospital
-
Montreal, Quebec, Canada, H2X 3J4
- Centre Hospitalier de l'Universite de Montreal
-
Quebec City, Quebec, Canada, G1R 2J6
- Centre de recherche du CHUQ
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- BCG Oncology
-
-
California
-
San Diego, California, United States, 92120
- San Diego Clinical Trials
-
-
Connecticut
-
New Britain, Connecticut, United States, 06052
- Connecticut Urological Research at Grove Hill
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami School of Medicine
-
Orlando, Florida, United States, 32803
- Winter Park Urology Associates P.A.
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- The University of Chicago Hospitals
-
-
Indiana
-
Evansville, Indiana, United States, 47713
- Welborn Clinic
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Johns Hopkins University
-
Towson, Maryland, United States, 21204
- Chesapeake Urology Research Associates
-
-
Nevada
-
Las Vegas, Nevada, United States, 89148
- Sheldon J Freedman, MD, Ltd
-
-
New Jersey
-
Voorhees, New Jersey, United States, 08043
- Delaware Valley Urology, LLC-Voorhees
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan Kettering Cancer Centre
-
Poughkeepsie, New York, United States, 12601
- Hudson Valley Urology
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Triangle Urology Group
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75231
- Urology Clinics of North Texas, P.A.
-
Houston, Texas, United States, 77030
- M.D. Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- Urology San Antonio Research, PA
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Sentara Medical Group - Urology of Virginia, PC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients refractory to BCG therapy;
- Patients with histologically confirmed diagnosis of high grade lesions;
- Diagnosis of high grade lesion must be within 56 days prior to beginning of study treatment;
- Have had all visible papillary lesion(s) resected by TURBT within 56 days prior to beginning of study treatment;
- Available for the whole duration of the study including follow-up (60 months);
- Life expectancy of > 5 years;
- Patients with an ECOG performance status grade of 2 or less;
- Absence of urothelial carcinoma involving the upper urinary tract or prostatic urethra within 12 months from beginning of study treatment;
- Able to understand and give written informed consent;
- In the investigator's judgment, the patient is able to participate in the study.
Exclusion Criteria:
- Current or previous history of muscle invasive tumors;
- Current or previous history of lymph node or distant metastases from bladder cancer;
- Current systemic cancer therapy;
- Current or prior pelvic external beam radiotherapy;
- Pelvic brachytherapy within 2 years of study entry;
- Prior treatment with MCC;
- Patients with existing urinary tract infection or recurrent severe bacterial cystitis;
- Clinically significant and unexplained elevations of liver or renal function tests;
- White blood cell count below 3 x109/L (3,000/mm3) or platelet count below 100 x 109/L(100,000/mm3);
- Severe cardiovascular disease;
- Women who are pregnant or lactating;
- Congenital or acquired immune deficiency;
- With history of malignancy of any organ system, treated or untreated, within the past 5 years (with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, stage T1 prostate cancer, carcinoma in situ of the cervix or colon polyps);
- Previous investigational treatment within 3 months from beginning of study treatment;
- Patients who cannot hold the instillation for one hour;
- Patients who cannot tolerate intravesical administration or intravesical surgical manipulation (cystoscopy or biopsy);
- Clinically significant active infections;
- Any medical or psychiatric condition which, in the opinion of the investigator, would preclude the participant from adhering to the protocol or completing the trial per protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Mycobacterial cell wall-DNA complex
|
8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
One year disease-free survival rate
Time Frame: Prospective
|
Prospective
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The 3, 6 and 24 month disease-free survival rate
Time Frame: Prospective
|
Prospective
|
Duration of disease-free survival in all patients
Time Frame: Prospective
|
Prospective
|
Time to progression to muscle invasive disease
Time Frame: Prospective
|
Prospective
|
Overall survival in all patients
Time Frame: Prospective
|
Prospective
|
Rate of overall drug-related adverse events leading to two consecutive treatment delays of one week each or to the discontinuation of treatment.
Time Frame: Prospective
|
Prospective
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alvaro Morales, MD, Centre for Applied Urological Research, Kingston General Hospital/Queen's University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HIS-0611-0602
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Neoplasms
-
Peking University First HospitalRecruitingUrinary Bladder Cancer | Bladder Cancer | Bladder Neoplasms | Bladder Tumors | Neoplasms, BladderChina
-
Mansoura UniversityCompletedBladder Cancer | Bladder Disease | Bladder Neoplasm | Micro-RNAEgypt
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Medical Enterprises Ltd.TerminatedUrinary Bladder Cancer | Bladder Cancer | Malignant Tumor of Urinary Bladder | Bladder Neoplasm | Cancer of Bladder | Carcinoma in Situ of Bladder | Bladder Tumors | Cancer of the Bladder | Neoplasms, Bladder | Papillary Carcinoma of Bladder (Diagnosis) | BCG-Unresponsive Bladder CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Baylor College of MedicinePfizerTerminatedBladder Cancer | Invasive Bladder Cancer | Metastatic Bladder CancerUnited States
-
Fundacio PuigvertKARL STORZ Endoscopy-America, Inc.RecruitingBladder Cancer | Urothelial Carcinoma BladderSpain
Clinical Trials on Mycobacterial cell wall-DNA complex
-
Bioniche Life Sciences Inc.Withdrawn
-
M.D. Anderson Cancer CenterRecruiting
-
Nabeel HamzehRecruitingHealthy | ST Elevation Myocardial Infarction | Sarcoidosis | Sarcoidosis With MyocarditisUnited States
-
Institut du Cancer de Montpellier - Val d'AurelleCompleted
-
University of MinnesotaUniversity of HawaiiNot yet recruiting
-
Peking Union Medical College HospitalUnknown
-
Loma Linda UniversityRecruitingGraft Failure | Acute Rejection of Renal TransplantUnited States
-
Puerta de Hierro University HospitalRecruitingHeart Transplant RejectionSpain
-
Postgraduate Institute of Medical Education and...RecruitingHepatic Carcinoma Malignant Primary Non-ResectableIndia
-
Paris Translational Research Center for Organ TransplantationCompletedKidney Rejection Transplant